Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/Hyperactivity Disorder

Author:

Greenhill L.1,Beyer D. H.2,Finkleson J.3,Shaffer D.3,Biederman J.4,Conners C. K.5,Gillberg C.6,Huss M.7,Jensen P.3,Kennedy J. L.8,Klein R.9,Rapoport J.10,Sagvolden T.11,Spencer T.11,Swanson J. M.12,Volkow N.13

Affiliation:

1. New York State Psychiatric Institute/Columbia University and is Senior Editor of the Journal of Attention Disorders.

2. Novartis Pharmaceuticals.

3. New York State Psychiatric Institute/Columbia University.

4. Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, and the Department of Psychiatry, Harvard Medical School, Boston.

5. Duke University Medical Center and is Editor-in-Chief of the Journal of Attention Disorders.

6. Department of Child and Adolescent Psychiatry, University of Göteborg, Sweden, and St George's Hospital Medical School, London.

7. Charité Virchow-Hospital, Humboldt-University of Berlin.

8. Centre for Addiction and Mental Health at the University of Toronto.

9. New York University Child Study Center in New York, NY.

10. Department of Physiology, University of Oslo, Norway.

11. Pediatric Psychopharm-acology Unit, Psychiatry Service, Massachusetts General Hospital, and the Department of Psychiatry, Harvard Medical School, Boston.

12. Child Development Center at the University of California, Irvine and the Sackler Institute at Cornell University in New York.

13. Department of Brookhaven National Laboratory and the State University of New York, Stony Brook.

Abstract

Objective: To review published algorithms for guiding the use of methylphenidate (MPH) in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Methods: A consensus roundtable of 12 experts was convened to review the evidence for the safety and efficacy of MPH in the treatment of ADHD, as well as the published algorithms and practice guidelines for using MPH. The experts reviewed the algorithms for practicality and acceptability by clinicians. Results: Algorithms that included MPH commonly selected it as the initial medication to be employed in the treatment of children with ADHD. Factors involved included its high efficacy, good safety record, and the ubiquitous nature of its appearance in the ADHD treatment literature. Conclusions: MPH should be considered as the first medication to be used in a treatment algorithm for children and adolescents with ADHD.

Publisher

SAGE Publications

Subject

Clinical Psychology,Developmental and Educational Psychology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3